Wockhardt shares advance 12% as net loss flips to profit of ₹78 crore in Q2

The stock closed 8.47% higher at ₹1,390.10 per equity share on Monday.

The scrip has gained 6.4% over the past five days but has lost nearly 5% over the month. It has advanced above 7% in the last six months. On a year-to-date basis, it has fallen 4.5%.

While the share reached a 52-week high of ₹1,110.05 on February 28, 2025, it touched a year’s high of ₹1,868.80 apiece on June 12, 2025.

Wockhardt Q2 results

It posted a consolidated net profit of ₹78 crore, compared to a net loss of ₹22 crore in the year-ago period, the firm said in a regulatory filing.

In the quarter-ago period, it had clocked a net loss of ₹90 crore.

The pharmaceutical company witnessed a 5.81% year-on-year (YoY) decline in its revenue from operations, which stood at ₹762 crore during the quarter under review, as against ₹809 crore in the September quarter of the 2024-25 fiscal year (Q2FY25).

Sequentially, however, its revenue increased by 3.25% QoQ from ₹738 crore in the first quarter of FY26.

During the quarter, its innovative portfolio, which includes novel antibiotics and biotechnology, contributed 22% to the company’s revenue, it said in a press release.

At an operational level, the drugmaker’s EBITDA (earnings before interest, tax, depreciation and amortisation), also known as operating profit, stood at ₹160 crore in the September quarter of the current fiscal year, marking a 15.12% YoY surge from ₹139 crore in the corresponding period of the previous fiscal year. Furthermore, it was up 58% QoQ from ₹101 crore in the quarter-ago period.

Its EBITDA margin expanded by basis points (bps) YoY to 20.5% in Q2FY26, compared to 17% in the second quarter of FY25. In Q1FY26, the margin stood at 13.7%.

Wockhardt has a total market capitalisation of ₹22,588.04 crore, as of November 3, 2025, according to data on the NSE.